First digital pill raises 'Big Brother' concerns

For the first time, the Food and Drug Administration has approved a digital pill - a medication embedded with a sensor that can tell doctors whether, and when, patients take their medicine.

The approval, announced late on Monday, marks a significant advance in the growing field of digital devices designed to monitor medicine-taking and to address the expensive, long-standing problem that millions of patients do not take drugs as prescribed.

Experts estimate that so-called nonadherence or noncompliance to medication costs about $100 billion a year, much of it because patients get sicker and need additional treatment or hospitalisation.

"When patients don't adhere to lifestyle or medications that are prescribed for them, there are really substantive consequences that are bad for the patient and very costly," said Dr William Shrank, chief medical officer of the health plan division at the University of Pittsburgh Medical Center.

Ameet Sarpatwari, an instructor in medicine at Harvard Medical School, said the digital pill "has the potential to improve public health," especially for patients who want to take their medication but forget. But, he added, "if used improperly, it could foster more mistrust instead of trust."

Patients who agree to take the digital medication, a version of the antipsychotic Abilify, can sign consent forms allowing their doctors and up to four other people, including family members, to receive electronic data showing the date and time pills are ingested.

A smartphone app will let them block recipients anytime they change their mind. Although voluntary, the technology is still likely to prompt questions about privacy and whether patients might feel pressure to take medication in a form their doctors can monitor.

Dr Peter Kramer, a psychiatrist and the author of "Listening to Prozac," raised concerns about "packaging a medication with a tattletale." While ethical for "a fully competent patient who wants to lash him or herself to the mast," he said, "'digital drug' sounds like a potentially coercive tool."

Other companies are developing digital medication technologies, including another ingestible sensor and visual recognition technology capable of confirming whether a patient has placed a pill on the tongue and has swallowed it.

Not all will need regulatory clearance, and some are already being used or tested in patients with heart problems, stroke, HIV, diabetes and other conditions.

Because digital tools require effort, like using an app or wearing a patch, some experts said they might be most welcomed by older people who want help remembering to take pills and by people taking finite courses of medication, especially for illnesses like tuberculosis, in which nurses often observe patients taking medicine.

The technology could potentially be used to monitor whether post-surgical patients took too much opioid medication or clinical trial participants correctly took drugs being tested.

Insurers might eventually give patients incen-
tives to use them, like discounts on copayments,
said Dr Eric Topol, director of Scripps Translational Science Institute, adding that ethical issues could arise if the technology was "so much incentivised that it's almost is like coercion."

Another controversial use might be requiring digital medicine as a condition for parole or releasing patients committed to psychiatric facilities.

Abilify is an arguably unusual choice for the first sensor-embedded medicine. It is prescribed to people with schizophrenia, bipolar disorder and, in conjunction with an antidepressant, major depressive disorder.

"Many of those patients don't take meds because they don't like side effects, or don't think they have an illness, or because they become paranoid about the doctor or the doctor's intentions," said Dr Paul Appelbaum, director of law, ethics and psychiatry at Columbia University's psychiatry department.

"A system that will monitor their behaviour and send signals out of their body and notify their
doctor?" he added. "You would think that, whet her in psychiatry or general medicine, drugs for almost any other condition would be a better place to start than a drug for schizophrenia."

The newly approved pill, called Abilify MyCite, is a collaboration between Abilify's manufacturer, Otsuka, and Proteus Digital Health, a California company that created the sensor.

The sensor, containing copper, magnesium and silicon (safe ingredients found in foods), generates an electrical signal when splashed by stomach fluid, like a potato battery, said Andrew Thompson, Proteus' president and chief executive. After several minutes, the signal is detected by a Band-Aid-like patch that must be worn on the left rib cage and replaced after seven days, said Andrew Wright, Otsuka America's vice president for digital medicine.

The patch sends the date and time of pill ingestion and the patient's activity level via Bluetooth to a cellphone app. The app allows patients to add their mood and the hours they have rested, then transmits the information to a database that physicians and others who have patients' permission can access.

Otsuka has not determined a price for Abilify MyCite, which will be rolled out next year, first to a limited number of health plans, Wright said. The price, and whether digital pills improve adherence, will greatly affect how widely they are used. Questions about the technology's ability to increase compliance remain.

Concerns of coercion

Dr Jeffrey Lieberman, chairman of psychiatry at Columbia University and NewYork-Presbyterian Hospital, said many psychiatrists would likely want to try digital Abilify, especially for patients who just experienced their first psychotic episode and are at risk of stopping medication after feeling better. But he noted it has only been approved to track doses, and has not yet been shown to improve adherence.

"Is it going to lead to people having fewer relapses, not having unnecessary hospital readmissions, being able to improve their vocational and social life?" he asked. He added, "There's an irony in it being given to people with mental disorders than can include delusions. It's like a biomedical Big Brother."

Seeking to address concerns about privacy and coercion, Otsuka officials contracted with several bioethicists. Among them, I Glenn Cohen, a Harvard law professor, said safeguards adopted include allowing patients to instantly stop physicians and others from seeing some or all of their data.

Asked whether it might be used in circumstances like probation or involuntary hospitalisation,
Otsuka officials said that was not their intention or expectation, partly because Abilify MyCite only
works if patients want to use the patch and app.

How patients will view Abilify MyCite is unclear. Tommy, 50, of Queens, New York, who takes Abilify for schizoaffective disorder, participated in a clinical trial for digital Abilify.

Tommy, who withheld his last name to protect his privacy, encountered minor issues, saying the patch was "a little bit uncomfortable" and once gave him a rash.

A compliant patient, Tommy said he does not need monitoring. "I haven't had paranoid thoughts for a long time - it's not like I believe they're beaming space aliens," he said. If offered digital Abilify, he said, "I wouldn't do it again."

But the method might appeal to patients who want to prove their compliance, build trust with their psychiatrist, or who feel "paranoid about getting accused of not taking their medicine."